4D Molecular Therapeutics, Inc. (FDMT) bonds
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/302% above fair value
$12.23+0.12 (+0.95%)
Close on Nov 13, 2026Market cap $882.76MP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Total debt
$19.68M
Long-term debt
Net debt
-$19.43M
After $39.10M of cash
Implied interest rate
–
FY2025 interest ÷ average debt
Interest coverage
–
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Notes and loans outstanding
As tagged in 4D Molecular Therapeutics's 10-Q for the period ended Jun 30, 2026
4D Molecular Therapeutics's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Available | Drawn | Expires |
|---|---|---|---|---|
| Hercules Loan Facility | $50.00M | $30.00M | $21.30M | Jun 1, 2031 |
See a number that looks wrong?